Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

T. Zhou; Y. Yang; S. Ma; L. Lin; T. Zhou; C. Zhang; X. Ding; R. Wang; G. Feng; Y. Chen; R. Xu; Y. Huang; L. Zhang

doi:10.1016/j.esmoop.2021.100313

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

ESMO Open ◽

10.1016/j.esmoop.2021.100313 ◽

2021 ◽

Vol 6 (6) ◽

pp. 100313

Author(s):

T. Zhou ◽

Y. Yang ◽

S. Ma ◽

L. Lin ◽

T. Zhou ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Metastatic Nasopharyngeal Carcinoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial

Haematologica ◽

10.3324/haematol.2019.220301 ◽

2019 ◽

Vol 105 (1) ◽

pp. e29-e32 ◽

Cited By ~ 2

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Hemophagocytic Lymphohistiocytosis ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial

Annals of Oncology ◽

10.1093/annonc/mdx374.009 ◽

2017 ◽

Vol 28 ◽

pp. v376-v377

Author(s):

L. Zhang ◽

Y. Huang ◽

Y. Yang ◽

S. Ma ◽

X. Lin ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

Open Label ◽

Metastatic Nasopharyngeal Carcinoma ◽

Open Label Phase

Download Full-text

P3-14-15: Non-Randomized, Open Label Phase II Trial Evaluating the Safety and Efficacy of Taxotere (T) Followed by Myocet (M) + Cyclophosphamide (C) as First-Line Treatment for HER2−Negative Breast Cancer (BC).

10.1158/0008-5472.sabcs11-p3-14-15 ◽

2011 ◽

Cited By ~ 1

Author(s):

J García-Mata ◽

L Calvo ◽

R López ◽

M Ramos ◽

J Castellanos ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Investigational New Drugs ◽

10.1007/s10637-018-0599-4 ◽

2018 ◽

Vol 36 (4) ◽

pp. 674-682 ◽

Cited By ~ 1

Author(s):

Arthur Lui ◽

Karen Mulder ◽

Christine Brezden-Masley ◽

Michael Vickers ◽

Jose Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer.

10.1158/1535-7163.targ-13-a75 ◽

2013 ◽

Author(s):

Lorraine Chantrill ◽

Amber Johns ◽

Adnan Nagrial ◽

Venessa Chin ◽

Angela Chou ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii Trial ◽

Molecular Signature ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Pancreatic Cancer Therapy ◽

The Impact ◽

First Line Treatment

Download Full-text

First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7591 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7591-7591 ◽

Cited By ~ 2

Author(s):

J. Liang ◽

M. Ahn ◽

J. Kang ◽

Q. Xiu ◽

Y. Chen ◽

...

Keyword(s):

Phase Ii ◽

Advanced Nsclc ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Never Smoker ◽

First Line Treatment

Download Full-text

1404P Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1513 ◽

2021 ◽

Vol 32 ◽

pp. S1058

Author(s):

J. Wang ◽

T. Wu ◽

Y-G. Hong ◽

S-X. Luo ◽

N. Li ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4032 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4032-4032

Author(s):

Arthur Gregory Ang Lui ◽

Karen E. Mulder ◽

Christine Brezden-Masley ◽

Michael M. Vickers ◽

Jose Gerard Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Annals of Oncology ◽

10.1093/annonc/mdq247 ◽

2010 ◽

Vol 21 (11) ◽

pp. 2213-2219 ◽

Cited By ~ 80

Author(s):

S. Rao ◽

N. Starling ◽

D. Cunningham ◽

K. Sumpter ◽

D. Gilligan ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

European Journal of Cancer ◽

10.1016/j.ejca.2020.12.029 ◽

2021 ◽

Vol 146 ◽

pp. 95-106

Author(s):

M. Haas ◽

D.T. Waldschmidt ◽

M. Stahl ◽

A. Reinacher-Schick ◽

J. Freiberg-Richter ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Metastatic Pancreatic Cancer ◽

Integrated Analysis ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text